Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Sir_Holleron Jul 30, 2015 11:30am
107 Views
Post# 23975946

RE:RE:RE:RE:RE:RE:RE:Quarterly Report

RE:RE:RE:RE:RE:RE:RE:Quarterly Report
Rob actually says, re TAAs, "we're actually seeing now revenue starting to flow from those agreements and that's covering the overhead of the company" (04:14, https://www.youtube.com/watch?v=JlEkluUQ-V4).
------------

BTI has multiple corporate agreements. The MD&A didn't specify THESE WERE DEALS WITH COMPANIES, IF I REMEMBER CORRECTLY. Now, BTI has reported 'remarkable' results with Scarpa in an MD&A, and a number of TAAs covering the overhead of the company. Once the Scarpa results are revealed to the market the may increase the odds of these agreements moving forward. Hopefully the market is excited as Rob. More clarity from Medimmune and its future intentions would seal the deal. The Herceptin data would support the Harvard collaboration. Scarpa may move the Lysosomal Storage Disease program forward in Europe.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities